Company Overview and News
Investors with an interest in Schools stocks have likely encountered both American Public Education (APEI - Free Report) and Strayer Education (STRA - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
Have you been paying attention to shares of Grand Canyon Education (LOPE - Free Report) ? Shares have been on the move with the stock up 7.3% over the past month. LOPE hit a new 52-week high of $112.94 in the previous session. Grand Canyon Education has gained 23.2% since the start of the year compared to the 2.1% move for the Consumer Discretionary sector and the 18.7% year-to-date return for its peer group.
MOV LOPE IMMR ALIMR GTS CECO WTW MOVAA STRA
Shares of American Public Education (APEI - Free Report) have rallied 65.3% so far this year, outperforming the 21.2% gain of the industry it belongs to. Also, the company has outperformed the industry in the 12-week and 52-week frame, giving the stock a Momentum Score of A. Strategic Initiatives, new courses and strong digital marketing campaigns bode well. The company’s consistent bottom-line outperformance has lent the stock some momentum.
LOPE DUKH APEI DUK BFAM STRA
American Public Education, Inc. (APEI - Free Report) reported first-quarter 2018 earnings per share of 35 cents, beating the Zacks Consensus Estimate of 34 cents. Adjusted earnings in the year-ago quarter were 28 cents. Revenues and Enrollment Total revenues of $75 million met the Zacks Consensus Estimate. Also, revenues fell 1% year over year, thanks to lower contribution from the American Public Education segment (“APEI”).
APEI MYGN STRA ATGE
Adtalem Global Education Inc. (ATGE - Free Report) reported third-quarter fiscal 2018 results, with earnings surpassing the Zacks Consensus Estimate but revenues missing the same. Adjusted earnings of 72 cents per share surpassed the Zacks Consensus Estimate of 71 cents. On a year-over-year basis, earnings increased 22%. Quarterly revenues of $342.2 million marginally missed the Zacks Consensus Estimate of $343.
APEI AUY YRI LVS STRA ATGE
Universal Technical Institute, Inc. (UTI - Free Report) reported adjusted loss of 40 cents per share in the second quarter of fiscal 2018, wider than the Zacks Consensus Estimate of a loss of 19 cents. The loss figure was also wider than the year-ago quarter’s loss of 12 cents. Revenues & Enrollment Revenues of $80.7 million in the second quarter fell 2.2% from $82.5 million in the prior-year quarter.
APEI AUY YRI UTI LVS STRA
stra_Current_Folio_10Q Table of Contents
Strayer Education Inc. (STRA - Free Report) reported first-quarter 2018 adjusted earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.11 by 10.8%. However, earnings improved 29.5% year over year. Revenues improved 1.4% from the prior-year quarter to $116.5 million, owing to higher winter term enrollment. The upside was partly offset by lower revenue per student, given the continuing effect of scholarships issued in the fall 2017 term.
APEI STRA ATGE MRC
Shares of Capella Education Company (CPLA - Free Report) gained 6.4% on May 2, following first-quarter 2018 earnings release. The company reported adjusted earnings of $1.20 per share in the quarter, which surpassed the Zacks Consensus Estimate of $1.16 by 3.5%. In the year-ago quarter, earnings were 94 cents. Revenues and Enrollment Capella’s quarterly revenues of $112 million missed the Zacks Consensus Estimate of $113 million and increased a meagre 0.
APEI UBS UBS.PRDCL UTI STRA ATGE ULSGF
Good morning, everyone, and welcome to Strayer Education Incorporated’s First Quarter 2018 Earnings Results Conference Call. This call is being recorded. For those of you who wish to listen to the conference via the Internet, please go to strayereducation.com, where the call will be archived.
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
2018-06-11 - Asif
Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...
Silicon Investor Message Boards
This table lists all message boards related to STRA / Strayer Education, Inc. on message board site Silicon Investor.
as of ET